Zinc-[gamma]-PGA compositions and methods for treating cancer
The invention relates to pharmaceutical compositions comprising a zinc 2+ salt and a γ-polyglutamic acid carrier, and, optionally, an NF-kB inhibitor as a tumor-sensitizing agent, and methods for using such compositions to treat tumors in patients. Methods include administering a liquid dosage form or a solid dosage form of a therapeutically effective amount of a Zn(II) salt and a γ-polyglutamic acid carrier to a patient in need thereof. Methods of treating a broad spectrum of human tumors, including tumors with a drug-resistant phenotype, using the disclosed compositions are provided. Tumors that respond to the pharmaceutical compositions disclosed herein include neuroendocrine (neuroblastoma), gastric, uterine, and lung tumors.
1. A method of inducing PARP1-mediated tumor necrosis in a tumor in a patient, the method comprising administering a therapeutically effective amount of Zn(II) complexed to a carboxylate moiety of γ-polyglutamic acid in a γ-polyglutamic acid carrier in a dosage form to the patient with the tumor;
wherein said tumor has a drug-resistant phenotype selected from dysfunctional p53, MDR1 overexpression, and MRP1 overexpression.
2. The method according to claim 1 , wherein said Zn(II) complexed with said γ-polyglutamic acid carrier in said dosage form are administered in a therapeutic amount in combination with a therapeutic amount of a nuclear factor kappa B (NF-κB) inhibitor.
3. The method according to claim 1 or 2 , wherein said dosage form is a solid dosage form or a liquid dosage form.
4. The method according to claim 3 , wherein said dosage form is a solid dosage form, and is selected from a tablet, a minitab, a hard capsule, a soft capsule, a caplet, a gelcap, an oral disintegrating film, granules, pellets, a paste, and a powder sachet.
5. The method according to claim 3 , wherein said dosage form is a liquid dosage form, and is selected from a liquid solution, a liquid suspension, a syrup, and an oral spray.
6. The method according to claim 3 , wherein said administering step is selected from an oral administration and an injection administration.